| Literature DB >> 32636938 |
Jin-Rui Wang1, Zhongli Chen2, Ke Yang2, Hui-Jun Yang1, Wen-Yu Tao1, Yi-Ping Li1, Ze-Jia Jiang3, Chao-Fang Bai1, Yue-Chuan Yin1, Jian-Mei Duan1, Yuan-Yuan Zhou1, Xin-Qian Geng1, Ying Yang1.
Abstract
BACKGROUND: Diabetic retinopathy (DR) is a specific neurovascular complication of diabetes mellitus (DM). Clinically, family history is a widely recognized risk factor for DR, assisting diagnosis and risk strata. However, among a great amount of DR patients without hereditary history like hypertension and diabetes, direct and simple risk factors to assist clinical decisions are still required. Herein, we intend to investigate the associated risk factors for these DR patients based on systemic inflammatory response indexes, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).Entities:
Keywords: Diabetic retinopathy; Family history; Hemoglobin; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Type 2 diabetes mellitus
Year: 2020 PMID: 32636938 PMCID: PMC7331251 DOI: 10.1186/s13098-020-00562-y
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Baseline characteristics of the DR and NDR groups
| Variable | DR group N = 264 | NDR group N = 206 | |
|---|---|---|---|
| Gender (male/female) | 131/133 | 146/60 | 0.000** |
| Hypertension (no/yes) | 95/169 | 108/98 | 0.000** |
| Smoking (no/yes) | 168/96 | 107/99 | 0.007* |
| Drinking (no/yes) | 180/84 | 119/87 | 0.013* |
| Sulfonylureas (no/yes) | 147/117 | 110/96 | 0.344 |
| Biguanides (no/yes) | 129/135 | 95/110 | 0.327 |
| Insulin (no/yes) | 127/137 | 108/98 | 0.201 |
| Age (years) | 56.48 ± 9.86 | 55.44 ± 11.27 | 0.295 |
| NLR | 2.36 ± 1.16 | 1.97 ± 1.06 | 0.000** |
| MLR (*10) | 2.28 ± 1.03 | 2.34 ± 1.28 | 0.628 |
| PLR (*0.1) | 11.62 ± 4.55 | 10.56 ± 4.45 | 0.012* |
| Neutrophils (*109/L) | 4.25 ± 1.31 | 3.72 ± 1.22 | 0.000** |
| Lymphocytes (*109/L) | 1.98 ± 0.64 | 2.11 ± 0.67 | 0.031* |
| Monocytes (*109/L) | 0.42 ± 0.15 | 0.44 ± 0.15 | 0.097 |
| Platelets (*109/L) | 213.84 ± 69.19 | 203.90 ± 54.66 | 0.092 |
| Diabetes course (month) | 122.86 ± 87.38 | 66.16 ± 66.25 | 0.000** |
| BMI (kg/m2) | 24.12 ± 3.25 | 24.62 ± 3.14 | 0.090 |
| FPG (mmol/L) | 9.60 ± 3.79 | 8.80 ± 3.27 | 0.019 * |
| HbA1c (%) | 9.96 ± 2.45 | 9.68 ± 2.66 | 0.246 |
| WBC (*109/L) | 6.83 ± 1.65 | 6.45 ± 1.50 | 0.010* |
| Hb (g/L) | 136.25 ± 19.33 | 153.20 ± 15.70 | 0.000** |
| BUN (mmol/L) | 7.07 ± 7.82 | 5.32 ± 1.64 | 0.000** |
| Scr (mmol/L) | 84.21 ± 46.63 | 69.14 ± 17.87 | 0.000** |
| TG (mg/dL) | 3.02 ± 2.37 | 2.29 ± 1.99 | 0.000** |
| TC (mg/dL) | 4.73 ± 2.09 | 4.79 ± 1.13 | 0.694 |
| HDL-C (mg/dL) | 1.16 ± 0.33 | 1.12 ± 0.57 | 0.434 |
| LDL-C (mg/dL) | 3.11 ± 0.98 | 2.97 ± 0.88 | 0.110 |
DR diabetic retinopathy, NDR non-diabetic retinopathy, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, WBC white blood cell, Hb hemoglobin, BUN blood urea nitrogen,Scr serum creatinine,TG triglycerides, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
*P < 0.05, **P < 0.01
Fig. 1Comparison of NLR and PLR in different group a Boxplot showed that DR patients had higher NLR than the NDR patients (p < 0.001**). b Boxplot showed that DR patients had higher PLR than the NDR patients (p = 0.012)
Correlation analysis of NLR, PLR and Hb and major clinical factors
| Variable | NLR | PLR (*0.1) | Hb(g/L) | |||
|---|---|---|---|---|---|---|
| R | R | R | ||||
| Gender (male/female) | −0.061 | 0.190 | 0.080 | 0.082 | −0.465 | 0.000** |
| Hypertension (no/yes) | 0.053 | 0.247 | −0.008 | 0.855 | −0.130 | 0.005** |
| Age (years) | 0.055 | 0.238 | 0.029 | 0.534 | −0.150 | 0.001** |
| NLR | 1 | 1 | 0.520 | 0.000** | −0.115 | 0.012* |
| MLR (*10) | 0.609 | 0.000** | 0.446 | 0.000** | 0.004 | 0.934 |
| PLR (*0.1) | 0.520 | 0.000** | 1 | 1 | −0.289 | 0.000** |
| Diabetes course (month) | 0.125 | 0.007** | 0.093 | 0.044* | −0.266 | 0.000** |
| BMI (kg/m2) | −0.021 | 0.651 | −0.117 | 0.011* | 0.194 | 0.000** |
| FPG (mmol/L) | 0.015 | 0.755 | −0.063 | 0.184 | 0.080 | 0.091 |
| HbA1c (%) | −0.001 | 0.980 | −0.072 | 0.129 | 0.076 | 0.110 |
| Hb (g/L) | −0.115 | 0.012* | −0.289 | 0.000** | 1 | 1 |
| BUN (mmol/L) | 0.100 | 0.033* | −0.042 | 0.371 | −0.220 | 0.000** |
| Scr (mmol/L) | 0.173 | 0.000** | 0.079 | 0.092 | −0.065 | 0.168 |
| Sulfonylureas (no/yes) | −0.078 | 0.090 | 0.049 | 0.291 | -0.016 | 0.725 |
| Biguanides (no/yes) | 0.033 | 0.476 | −0.058 | 0.209 | 0.072 | 0.120 |
| Insulin (no/yes) | 0.081 | 0.081 | −0.032 | 0.491 | 0.009 | 0.839 |
NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, Hb hemoglobin, BUN blood urea nitrogen, Scr serum creatinine, R correlation coefficient
*P < 0.05, **P < 0.01
Univariate analysis
| Variable | OR | 95%CI lower | 95%CI upper | |
|---|---|---|---|---|
| Gender (Male/Female) | 2.47 | 1.68 | 3.63 | 0.000** |
| Hypertension (no/yes) | 1.96 | 1.35 | 2.84 | 0.000** |
| Age (years) | 1.01 | 0.99 | 1.03 | 0.295 |
| NLR | 1.46 | 1.19 | 1.79 | 0.000** |
| MLR (*10) | 0.96 | 0.82 | 1.13 | 0.619 |
| PLR (*0.1) | 1.06 | 1.01 | 1.10 | 0.013* |
| Diabetes course (month) | 1.01 | 1.01 | 1.01 | 0.000** |
| BMI (Kg/m2) | 0.95 | 0.90 | 1.01 | 0.090 |
| FPG (mmol/L) | 1.07 | 1.01 | 1.13 | 0.020* |
| HbA1c (%) | 1.05 | 0.97 | 1.13 | 0.239 |
| WBC (*109/L) | 1.17 | 1.04 | 1.31 | 0.010* |
| Hb (g/L) | 0.95 | 0.93 | 0.96 | 0.000** |
| BUN (mmol/L) | 1.42 | 1.26 | 1.59 | 0.000** |
| Scr (mmol/L) | 1.02 | 1.01 | 1.02 | 0.000** |
| TG (mg/dL) | 1.18 | 1.07 | 1.31 | 0.001** |
| TC (mg/dL) | 0.98 | 0.88 | 1.09 | 0.693 |
| HDL-C (mg/dL) | 1.21 | 0.76 | 1.93 | 0.412 |
| LDL-C (mg/dL) | 1.17 | 0.12 | 1.43 | 0.110 |
NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, WBC white blood cell, Hb Hemoglobin, BUN blood urea nitrogen,Scr serum creatinine,TG triglycerides, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, OR odds ratios, CI confidence intervals
*P < 0.05, **P < 0.01
Independent association between NLR and DR
| Exposure | Model | Model I | Model II |
|---|---|---|---|
| NLR group | OR (95%CI) | OR (95%CI) | OR (95%CI) |
| ContinuousNLR | 1.46 (1.19,1.78) 0.000** | 1.46 (1.18,1.81) 0.000** | 1.37 (1.06,1.78) 0.018* |
| 0.46–1.49 | 1 | 1 | 1 |
| 1.50-1.95 | 1.89 (1.12,3.17) 0.016* | 2.11 (1.19,3.73) 0.011* | 1.23 (0.62, 2.44) 0.556 |
| 1.95–2.54 | 2.25 (1.33,3.79) 0.002** | 2.51 (1.42,4.46) 0.002** | 1.77 (0.88, 3.55) 0.110 |
| 2.54–11.05 | 3.44 (2.01,5.89) 0.000** | 3.61 (1.99,6.55) 0.000** | 2.80 (1.32, 5.95) 0.007** |
| P for trend | 0.000** | 0.000** | 0.004** |
Model: crude model; Model I: adjusting for age, gender, diabetes duration; Model II: adjusting for age, gender, diabetes duration, hypertension, BMI, Scr, WBC, Hb, BUN, TG, FPG and HbA1c
NLR neutrophil-to-lymphocyte ratio,OR odds ratios, CI confidence intervals, BMI body mass index, Scr serum creatinine, WBC white blood cell, Hb hemoglobin, BUN blood urea nitrogen, TG triglycerides, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c
*P < 0.05, **P < 0.01
Independent association between PLR and DR
| Exposure | Model | Model I | Model II |
|---|---|---|---|
| PLRgroup | OR (95%CI) | OR (95%CI) | OR (95%CI) |
| Continuous PLR | 1.06 (1.01,1.10) 0.013* | 1.04 (0.99,1.09) 0.109 | 1.05 (0.99, 1.11) 0.135 |
| 2.75–7.98 | 1 | 1 | 1 |
| 7.99–10.34 | 1.65 (0.98, 2.76) 0.058 | 1.86 (1.06, 3.27) 0.031* | 1.37 (0.70, 2.71) 0.360 |
| 10.36–13.40 | 1.17 (0.70, 1.94) 0.558 | 1.34 (0.77, 2.34) 0.307 | 0.95 (0.47, 1.92) 0.891 |
| 13.49–35.26 | 2.51 (1.47, 4.27) 0.000** | 2.15 (1.20, 3.85) 0.001** | 2.20 (1.05, 4.59) 0.037* |
| P for trend | 0.003** | 0.033* | 0.073 |
Model: crude model; Model I: adjusting for age, gender, diabetes duration; Model II: adjusting for age, gender, diabetes duration, hypertension, BMI, Scr, WBC, Hb, BUN, TG, FPG and HbA1c
PLR platelet-to-lymphocyte ratio, OR odds ratios, CI confidence intervals, BMI body mass index, Scr serum creatinine, WBC white blood cell, Hb hemoglobin, BUN blood urea nitrogen, TG triglycerides, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c
*P < 0.05, **P < 0.01
Independent association between Hb and DR
| Exposure | Model | Model I | Model II |
|---|---|---|---|
| Hb group | OR (95%CI) | OR (95%CI) | OR (95%CI) |
| Continuous Hb | 0.95 (0.93, 0.96) 0.000** | 0.95 (0.94,0.97) 0.000** | 0.96 (0.94, 0.97) 0.000** |
| 70–132(g/L) | 1 | 1 | 1 |
| 133–143(g/L) | 0.32 (0.17, 0.61) 0.000** | 0.38 (0.19, 0.73) 0.004** | 0.88 (0.44, 1.74) 0.707 |
| 144–157(g/L) | 1.61 (0.95, 2.71) 0.076 | 2.02 (1.12, 3.62) 0.019* | 0.27 (0.12, 0.60) 0.001** |
| 158–195(g/L) | 0.07 (0.04, 0.13) 0.000** | 0.09 (0.05,0.20) 0.000** | 0.95 (0.93, 0.97) 0.000** |
| P for trend | 0.000** | 0.000** | 0.000** |
Model: Univariate model; Model I: adjusting for age, gender, and diabetes course; Model II: adjusting for age, gender, diabetes course, hypertension, BMI, Scr, WBC, NLR, PLR, BUN, TG, FPG, HbA1C
Hb hemoglobin, OR odds ratios, CI confidence intervals, BMI body mass index, Scr serum creatinine, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, BUN blood urea nitrogen, TG triglycerides, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c
*P < 0.05, **P < 0.01
A combination of PLR, NLR and Hb for predicting DR
| Marker | AUC | 95%CI lower | 95%CI upper | Cut off | Specificity | Sensitivity |
|---|---|---|---|---|---|---|
| NLR | 0.64 | 0.58 | 0.69 | 1.84 | 0.56 | 0.64 |
| PLR | 0.58 | 0.53 | 0.63 | 128.11 | 0.79 | 0.35 |
| Hb | 0.76 | 0.72 | 0.81 | 146.50 | 0.68 | 0.72 |
| NLR + PLR + Hb | 0.78 | 0.74 | 0.82 | – | 0.68 | 0.75 |
Based on model: logit (DR) = 8.74874−0.06060*Hb +0.49400*NLR−0.00682*PLR
AUC area under curve, CI confidence intervals, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, Hb hemoglobin, NRI net reclassification index, IDI integrated discrimination improvement
Fig. 2Receiver operating characteristic (ROC) curves of NLR, PLR and Hb for DR a The ROC curves using Hb, NLR or PLR alone for discriminating DR (Hb, black, NLR, red, PLR, green) b The ROC curves included and not included NLR and PLR for predicting DR, (Model1: black, a combination of NLR, PLR and Hb for predicting DR, Model2: red, using Hb along to predict DR)